A Double-Blind, Randomized, Parallel-Group Seasonal Allergic Rhinitis (SAR) Study to Evaluate the Efficacy, Safety and Tolerability of GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Olopatadine Hydrochloride Nasal Spray and Mometasone Furoate Nasal Spray) in Adult and Adolescent Subjects (12 Years of Age and Older)

Trial Profile

A Double-Blind, Randomized, Parallel-Group Seasonal Allergic Rhinitis (SAR) Study to Evaluate the Efficacy, Safety and Tolerability of GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Olopatadine Hydrochloride Nasal Spray and Mometasone Furoate Nasal Spray) in Adult and Adolescent Subjects (12 Years of Age and Older)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2017

At a glance

  • Drugs Mometasone/olopatadine (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals S.A.
  • Most Recent Events

    • 29 Mar 2017 According to a Glenmark Pharmaceuticals Ltd Media Release, data from this trial will be presented at upcoming scientific meetings and published in a peer-reviewed journal.
    • 29 Mar 2017 Primary endpoint has been met. (Change from baseline in average AM and PM subject-reported 12-hour reflective Total Nasal Symptom Score (rTNSS)), as reported in a Glenmark Pharmaceuticals Ltd Media Release.
    • 29 Mar 2017 Results published in the Glenmark Pharmaceuticals Ltd Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top